![]() However, 15% of COVID-19 patients may present with moderate symptoms, including headache, fever, sweating, arthralgia, myalgia, dry cough, and fatigue ( 4). Most COVID-19 patients are asymptomatic or present with mild flu-like illnesses in about 85% of the cases. Thus, we are challenged by the emergence of new strains that could be highly virulent and may cause the propagation of new waves. This new strain has been renamed as the XE variant of SARS-CoV-2, which is now with outstanding spread in China ( 3). Besides, a new mutant variant of Omicron SARS-CoV-2 BA1 and BA2 has been observed and detected in the United Kingdom, with about 637 confirmed cases. Up to date, a new variant strain of SARS-CoV-2 named the BA2 subtype has spread in specific regions of China. Different variants of SARS-CoV-2 strains emerged in the early months of 2020, and the last variant was Omicron SARS-CoV-2, which was mild with moderate transmission and low mortality ( 2). It has been shown that COVID-19 led to more than 500 million affected cases with more than 6 million confirmed deaths till late May 2022. COVID-19 is caused by novel virus known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) which produced a worldwide crisis with high morbidity and mortality ( 1). Taken together, these observations are untimely too early to give a final connotation between COVID-19 vaccination and the risk for development of hyperviscosity syndrome, consequently prospective and retrospective studies are necessary in this regard.Ĭoronavirus disease 2019 (COVID-19) is a current pandemic disease that began in Wuhan, China in late December 2019. Of interest, hyperviscosity syndrome is more commonly developed in vaccine recipients who had formerly received the COVID-19 vaccine due to higher underlying immunoglobulin concentrations, and only infrequently in those who have not received the COVID-19 vaccine. Most of the COVID-19 patients with a blood viscosity more than 3.5 cp may develop coagulation disorders. Of interest, hyperviscosity syndrome in COVID-19 may cause poor tissue perfusion, peripheral vascular resistance, and thrombosis. Variations in erythrocyte fragility and deformability with endothelial dysfunction and oxidative stress in SARS-CoV-2 infection may cause hyperviscosity syndrome in COVID-19. In COVID-19, SARS-CoV-2 may affect erythrocyte morphology via binding of membrane cluster of differentiation 147 (CD147) receptors, and B and 3 proteins on the erythrocyte membrane. Hyperviscosity syndrome is developed in different hematological disorders including multiple myeloma, sickle cell anemia, Waldenstorm macroglobulinemia, polycythemia, and leukemia. In order to review findings related to hyperviscosity in COVID-19, we suggested a protocol for narrative review of related published COVID-19 articles. Thus, this review aimed to study the link between SARS-CoV-2 infection and alteration of blood viscosity in COVID-19 patients. SARS-CoV-2-induced hyperinflammation together with alteration of plasma proteins, erythrocyte deformability, and platelet activation, may affect blood viscosity. ![]() 5Department of Pharmacology and Therapeutics, Faculty of Veterinary Medicine, Damanhour University, Damanhour, EgyptĬoronavirus disease 2019 (COVID-19) is caused by a novel virus known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).4Department of Pharmaceutical Microbiology, Faculty of Pharmacy, Tanta University, Tanta, Egypt.3Faculty of Medicine and Pharmacy, University of Oradea, Oradea, Romania.2Al-Mustansiriya University, Baghdad, Iraq.1Department of Clinical Pharmacology and Medicine, College of Medicine, Al-Mustansiriya University, Baghdad, Iraq.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |